Dermapharm Holding SE

DMP

DE000A2GS5D8

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:20 2024-04-19 am EDT			5-day change	1st Jan Change
31.9 ^EUR	+0.31%		-4.78%	-24.66%

Apr. 04	DERMAPHARM : Berenberg keeps its Buy rating	ZD
Mar. 28	Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

May 16, 2019 at 10:20 am EDT

DGAP Preliminary announcement financial reports: Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements
Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

16.05.2019 / 16:17
Preliminary announcement of the publication of quarterly reports and quarterly/interim statements transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Dermapharm Holding SE hereby announces that the following financial reports shall be disclosed :

Report: Quarterly/ Interim statement within the 1st half-year Date of disclosure / German: May 21, 2019 Date of disclosure / English: May 21, 2019 German: https://ir.dermapharm.de/#Finanzberichte English: https://ir.dermapharm.de/index-EN.php#Finanzberichte

16.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Dermapharm Holding SE
	Lil-Dagover-Ring 7
	82031 Grünwald
	Germany
Internet:	ir.dermapharm.de


End of News	DGAP News Service

812551 16.05.2019

Latest news about Dermapharm Holding SE

DERMAPHARM : Berenberg keeps its Buy rating	Apr. 04	ZD
Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15	Mar. 14	DP
Dermapharm looks cautiously into the future - missing Covid business	Mar. 14	DP
DERMAPHARM : Berenberg reaffirms its Buy rating	Dec. 07	ZD
DERMAPHARM : Berenberg reiterates its Buy rating	Nov. 16	ZD
Dpa-AFX Overview: COMPANIES from 15.11.2023 - 15:15	Nov. 15	DP
Dermapharm grows thanks to new subsidiary - nutritional supplements in demand	Nov. 15	DP
DERMAPHARM : Jefferies reiterates its Buy rating	Nov. 15	ZD
Dermapharm Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
Dermapharm grows thanks to subsidiary Arkopharma and dietary supplements	Nov. 15	DP
DERMAPHARM : Buy rating from Berenberg	23-10-19	ZD
DERMAPHARM : Berenberg maintains a Buy rating	23-09-21	ZD
Dermapharm Holding SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
DERMAPHARM : Jefferies keeps its Buy rating	23-08-29	ZD
Dermapharm move to SDax top - Jefferies praises profitability	23-08-16	DP
Dermapharm becomes more optimistic after first half-year - share price jumps	23-08-16	DP
Jefferies leaves Dermapharm at 'Buy' - Target 65 euros	23-08-16	DP
DERMAPHARM : Jefferies reiterates its Buy rating	23-08-16	ZD
Dermapharm becomes more optimistic after first half year	23-08-16	DP
Dermapharm Holding SE Provides Earnings Guidance for the Year 2023	23-08-16	CI
DERMAPHARM : Jefferies gives a Buy rating	23-08-14	ZD
DERMAPHARM : Berenberg keeps its Buy rating	23-06-20	ZD
WEEKLY PREVIEW: Dates until June 20, 2023	23-06-09	DP
WEEKLY PREVIEW: Dates until June 16, 2023	23-06-02	DP

Chart Dermapharm Holding SE

Duration

Period

More charts

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Dermapharm Holding SE

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.9 EUR

Average target price

57.9 EUR

Spread / Average Target

+81.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DERMAPHARM HOLDING SE	-24.66%	1.83B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals